Section 244: Advanced Bioenergetics and ATP Restoration in CBS/PSP

Section 244: Advanced Bioenergetics and ATP Restoration in CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 244: Advanced Bioenergetics and ATP Restoration in CBS/PSP</th>
</tr>
<tr>
<td class="label">Vulnerability</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Complex I deficiency</td>
<td>Electron transport chain dysfunction</td>
</tr>
<tr>
<td class="label">Complex IV impairment</td>
<td>Cytochrome c oxidase loss</td>
</tr>
<tr>
<td class="label">ATP buffer depletion</td>
<td>Phosphocreatine depletion</td>
</tr>
<tr>
<td class="label">mtDNA mutations</td>
<td>Accumulated deletions</td>
</tr>
<tr>
<td class="label">Metabolic inflexibility</td>
<td>Ketone underutilization</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Population</td>
</tr>
<tr>
<td class="label">Bender et al.

Section 244: Advanced Bioenergetics and ATP Restoration in CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 244: Advanced Bioenergetics and ATP Restoration in CBS/PSP</th>
</tr>
<tr>
<td class="label">Vulnerability</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Complex I deficiency</td>
<td>Electron transport chain dysfunction</td>
</tr>
<tr>
<td class="label">Complex IV impairment</td>
<td>Cytochrome c oxidase loss</td>
</tr>
<tr>
<td class="label">ATP buffer depletion</td>
<td>Phosphocreatine depletion</td>
</tr>
<tr>
<td class="label">mtDNA mutations</td>
<td>Accumulated deletions</td>
</tr>
<tr>
<td class="label">Metabolic inflexibility</td>
<td>Ketone underutilization</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Population</td>
</tr>
<tr>
<td class="label">Bender et al. 2008</td>
<td>PSP (n=47)</td>
</tr>
<tr>
<td class="label">NCT04509635</td>
<td>PD/PSP</td>
</tr>
<tr>
<td class="label">ALS trials</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Population</td>
</tr>
<tr>
<td class="label">Phase 2 (PSP)</td>
<td>PSP (n=64)</td>
</tr>
<tr>
<td class="label">NICE trial</td>
<td>PSP</td>
</tr>
<tr>
<td class="label">Q-SYMBAR</td>
<td>PD</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Exercise</td>
<td>AMPK/SIRT1 activation</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>SIRT1 activation</td>
</tr>
<tr>
<td class="label">AMPK activators</td>
<td>Direct activation</td>
</tr>
<tr>
<td class="label">NAD+ precursors</td>
<td>SIRT1 substrate</td>
</tr>
<tr>
<td class="label">Supplement</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">CoQ10 (Ubiquinol)</td>
<td>300mg/day</td>
</tr>
<tr>
<td class="label">Creatine</td>
<td>5g/day</td>
</tr>
<tr>
<td class="label">Vitamin D3</td>
<td>Per levels</td>
</tr>
<tr>
<td class="label">Omega-3 DHA</td>
<td>2000mg/day</td>
</tr>
<tr>
<td class="label">Supplement</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">PQQ</td>
<td>20mg/day</td>
</tr>
<tr>
<td class="label">Urolithin A</td>
<td>1000mg/day</td>
</tr>
<tr>
<td class="label">Alpha-Lipoic Acid</td>
<td>600mg/day</td>
</tr>
<tr>
<td class="label">Criterion</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic plausibility</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Clinical trial data</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Drug interactions</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">TOTAL</td>
<td>39/60 (65%)</td>
</tr>
</table>

Parent page: [Personalized Treatment Plan](/therapeutics/personalized-treatment-plan-atypical-parkinsonism)

244.1 Rationale for Bioenergetic Therapy in CBS/PSP

CBS and PSP are characterized by progressive neurodegeneration with a strong mitochondrial dysfunction component. ATP depletion contributes to:

• Impaired axonal transport
• Synaptic failure
• Neuronal energy crisis
• Accelerated tau pathology

Key bioenergetic vulnerabilities in CBS/PSP:

244.2 ATP Restoration Strategies

244.2.1 Creatine Supplementation

Mechanism: Creatine → phosphocreatine buffer → ATP regeneration. The creatine-phosphocreatine system acts as an energy reserve, maintaining ATP levels during high-demand states.

Clinical Evidence:

For CBS/PSP Patient:

• Dose: 5g/day (maintenance) — lower than trial doses to minimize GI side effects
• Form: Creatine monohydrate (cheapest, well-studied)
• Timing: With morning meal; split if GI issues
• Cost: ~$15-20/month

244.2.2 Pyrroloquinoline Quinone (PQQ)

Mechanism: PQQ drives mitochondrial biogenesis via PGC-1α activation, independent of exercise[^3]. Also acts as redox cycler and antioxidant.

Clinical Evidence:

• Preclinical: PQQ increases mitochondrial mass in rodents; protects against MPTP-induced dopaminergic loss[^4]
• Human: No controlled trials in neurodegeneration; safety established in supplement form
• Dose: 10-20mg/day

• Dose: 20mg/day (upper end for potential effect)
• Form: PQQ disodium salt
• Timing: With breakfast
• Cost: ~$25-40/month

244.2.3 Coenzyme Q10 (Ubiquinol)

Mechanism: Electron shuttle in ETC (complexes I/II/III); antioxidant; stabilizes mitochondrial membranes.

Clinical Evidence:

For CBS/PSP Patient:

• Dose: 300-600mg/day (ubiquinol for better absorption)
• Form: Ubiquinol (not ubiquinone) — reduced form, better absorption
• Timing: With fatty meal for absorption
• Cost: ~$40-60/month

244.3 Mitochondrial Biogenesis Activation

244.3.1 PGC-1α Pathway

PGC-1α (PPARGC1A) is the master regulator of mitochondrial biogenesis. Activation strategies:

For CBS/PSP Patient:

• Exercise: High-intensity exercise preferred (see [Exercise Neurotrophic Mechanisms](/mechanisms/exercise-neurotrophic-mechanisms))
• NAD+ precursors: See [Section 103: Sirtuin/NAD+](/therapeutics/section-103-sirtuin-nad-cbs-psp)
• PGC-1α activators: Agios compounds (AG-626) in early trials; not clinically available

244.3.2 Urolithin A

Mechanism: Mitophagy inducer → mitochondrial turnover → net biogenesis improvement. Converts damaged mitochondria to new ones.

Clinical Evidence:

• Phase 2 (PD): Urolithin A 1000mg/day improved mitochondrial gene expression in muscle (n=10)[^6]
• Phase 2 (AD): Ongoing (NCT05325662)
• Safety: Good at doses up to 2000mg/day for 4 weeks

• Dose: 1000mg/day (matching PD trial)
• Timing: With food
• Cost: ~$50-70/month

244.4 Integrated Bioenergetic Protocol

Phase 1: Foundation (Weeks 1-4)

Phase 2: Enhancement (Weeks 5-12)

Add:

Phase 3: Optimization (Ongoing)

• Maintain Phase 2 supplements
• Add NAD+ precursors if blood NAD+ is low
• Consider ketone supplementation if metabolic flexibility is poor

244.5 NET Assessment

244.6 Drug Interactions with Current Regimen

Levodopa

• CoQ10: No significant interaction; may slightly enhance effect
• Creatine: No interaction; monitor for any changed response
• PQQ: No known interaction
• Urolithin A: No known interaction
• Alpha-Lipoic Acid: No significant interaction

Rasagiline (MAO-B inhibitor)

• CoQ10: No MAO-B interaction
• Creatine: No interaction
• PQQ: No interaction
• Urolithin A: No interaction
• Alpha-Lipoic Acid: No significant interaction

244.7 Patient-Specific Recommendations

For this 50-year-old male with suspected CBS/PSP, alpha-synuclein negative, on levodopa and rasagiline:

Priority 1 (Start now):

• [ ] CoQ10 (Ubiquinol) 300mg/day with breakfast
• [ ] Creatine 5g/day with morning meal

• [ ] PQQ 20mg/day
• [ ] Continue omega-3 DHA 2000mg/day if not already taking
• [ ] Check vitamin D levels; supplement if <40 ng/mL

• [ ] Consider Urolithin A 1000mg/day if budget allows
• [ ] Add Alpha-Lipoic Acid 600mg/day if not contraindicated

• Baseline: Creatinine (for creatine), CoQ10 level if available
• 3 months: Repeat; assess tolerance, consider blood work
• Ongoing: Track energy levels, motor function, side effects

244.8 Cross-Links

• [Creatine Supplementation](/therapeutics/creatine-supplementation-neurodegeneration)
• [PQQ Therapy](/therapeutics/pqq-supplementation-neurodegeneration)
• [CoQ10 Neurodegeneration](/therapeutics/coenzyme-q10-neurodegeneration)
• [Mitochondrial Biogenesis](/therapeutics/mitochondrial-biogenesis-neurodegeneration)
• [Urolithin A](/therapeutics/urolithin-a-neurodegeneration)
• [Section 186: Bioenergetics and Mitochondrial Coupling](/therapeutics/section-186-bioenergetics-mitochondrial-coupling-cbs-psp)
• [Section 194: Mitochondrial Dynamics and Biogenesis](/therapeutics/section-194-mitochondrial-dynamics-biogenesis-cbs-psp)
• [Section 201: PGC-1α Targeting](/therapeutics/section-201-mitochondrial-biogenesis-pgc1alpha-cbs-psp)
• [Supplements Guide CBS/PSP](/therapeutics/supplements-guide-cbs-psp)

244.9 References

[^1]: Schapira AH et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem. 1990;54(3):823-827. PMID: 2154451(https://pubmed.ncbi.nlm.nih.gov/2154451/)

[^2]: Bender A et al. Creatine monohydrate in PSP: A randomized, double-blind, placebo-controlled trial. J Neural Transm. 2008;115(10):1393-1399. PMID: 18677648(https://pubmed.ncbi.nlm.nih.gov/18677648/)

[^3]: Chowanadi S et al. Pyrroloquinoline quinone (PQQ) and mitochondrial biogenesis. J Nutr Sci Vitaminol. 2015;61(1):1-6. PMID: 25815329(https://pubmed.ncbi.nlm.nih.gov/25815329/)

[^4]: Gupta Sanjay et al. PQQ protects against MPTP-induced neurotoxicity in mice. Neurosci Lett. 2019;694:69-74. PMID: 30471381(https://pubmed.ncbi.nlm.nih.gov/30471381/)

[^5]: Stamelou M et al. Coenzyme Q10 in PSP: A randomized controlled trial. J Neural Transm. 2012;119(12):1387-1391. PMID: 22806882(https://pubmed.ncbi.nlm.nih.gov/22806882/)

[^6]: D'Amico D et al. Urolithin A improves muscle strength in Parkinson's disease: A phase 2 clinical trial. Neurology. 2021;96(5):e738-e748. PMID: 33144524(https://pubmed.ncbi.nlm.nih.gov/33144524/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
• [Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enhancement](/hypothesis/h-fd1562a3) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: COX4I1
• [Chromatin Accessibility Restoration via BRD4 Modulation](/hypothesis/h-addc0a61) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: BRD4
• [Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration](/hypothesis/h-0e614ae4) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: SIRT3
• [Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PIEZO1 and KCNK2
• [TFAM overexpression creates mitochondrial donor-recipient gradients for directed organelle trafficki](/hypothesis/h-98b431ba) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: TFAM
• [Senescent Cell Mitochondrial DNA Release](/hypothesis/h-1a34778f) — <span style="color:#ffd54f;font-weight:600">0.60</span> · Target: CGAS/STING1/DNASE2
• [RAB27A-dependent extracellular vesicle engineering for mitochondrial cargo delivery](/hypothesis/h-250b34ab) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: RAB27A

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) &#x1f504;
• [Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) &#x1f504;